Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortization of Deferred Charges (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Amortization of Deferred Charges for 9 consecutive years, with -$78000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Amortization of Deferred Charges fell 139.39% to -$78000.0 in Q3 2023 year-over-year; TTM through Jun 2024 was -$78000.0, a 108.6% decrease, with the full-year FY2023 number at $455000.0, down 52.26% from a year prior.
  • Amortization of Deferred Charges was -$78000.0 for Q3 2023 at Cartesian Therapeutics, down from $135000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $398000.0 in Q1 2023 to a low of -$406000.0 in Q4 2020.
  • A 5-year average of $148526.3 and a median of $189000.0 in 2019 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 734.38% in 2020, then skyrocketed 314.0% in 2021.
  • Cartesian Therapeutics' Amortization of Deferred Charges stood at $64000.0 in 2019, then crashed by 734.38% to -$406000.0 in 2020, then soared by 152.22% to $212000.0 in 2021, then dropped by 16.98% to $176000.0 in 2022, then plummeted by 144.32% to -$78000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Amortization of Deferred Charges are -$78000.0 (Q3 2023), $135000.0 (Q2 2023), and $398000.0 (Q1 2023).